Phaseline

Targets › SLC6A9

SLC6A9 (Sodium- and chloride-dependent glycine transporter 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Psychiatry, Metabolic and endocrine; next expected readout Apr 2028.

Sodium- and chloride-dependent glycine transporter. Essential for regulating glycine concentrations at inhibitory glycinergic synapses..; FUNCTION: [Isoform GlyT-1B]: Sodium- and chloride-dependent glycine transporter..; FUNCTION: [Isoform GlyT-1C]: Sodium- and chloride-dependent glycine transporter. (UniProt, P48067)

Open in Phaseline: the race on SLC6A9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Disc MedicineBitopertin (DISC-1459)
Glycine transporter 1 inhibitor
SLC6A9Phase 3Erythropoietic Protoporphyria (EPP)–
National Cheng-Kung University HospitalSodium Benzoate
Glycine transporter 1 (GlyT1) inhibitor; increases synaptic glycine to enhance NMDA recept
SLC6A9Phase 2Symptom, CognitiveApr 2028

Conditions

Symptom, Cognitive (1) Erythropoietic Protoporphyria (EPP) (1)

Modalities

small molecule (2)

Companies

National Cheng-Kung University Hospital (1) Disc Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.